Introduction

Stomatitis herpetiformis represents a distinct subtype of recurrent oral ulceration characterized by the appearance of dozens to hundreds of grouped (herpetiform) small ulcers, typically 1-3 mm in diameter, that coalesce into larger erosions. Despite the traditional nomenclature suggesting herpes simplex virus (HSV) etiology, stomatitis herpetiformis occurs independently of HSV infection and instead represents a form of recurrent aphthous stomatitis (RAS) with unique clinical and potentially immunologic characteristics. This review examines clinical presentation, diagnostic criteria, differential diagnosis, and evidence-based pharmacologic management of this frequently misdiagnosed condition.

Clinical Features and Presentation

Characteristic Lesion Morphology

Stomatitis herpetiformis presents as multiple grouped ulcers appearing simultaneously or in rapid succession over 24-48 hours. Individual ulcers measure 1-2 mm in diameter (minor ulcerations) and typically number 10-100 per episode. The grouped arrangement creates networks of ulcers that frequently coalesce into larger erosive patches, sometimes measuring 5-10 mm in diameter.

The lesions exhibit classical aphthous characteristics: well-demarcated borders with erythematous haloes, yellowish-white fibrin-covered bases, and absence of vesicular precursors (critical distinction from HSV infection). Lesions occur predominantly on non-keratinized oral mucosa—ventral tongue, floor of mouth, buccal mucosa, and soft palate—though some cases show involvement of attached gingiva and hard palate.

Symptomatology and Functional Impact

Pain severity exceeds that typical of major aphthous ulcers despite smaller individual lesion size, primarily due to the multiplicative effect of numerous simultaneous lesions. Patients report inability to eat, drink, or maintain normal oral hygiene, with functional disability persisting 5-14 days per episode. Dysphagia occurs in approximately 30-40% of patients with extensive soft palate involvement.

Temperature elevation (low-grade fever, 37.5-38.5°C) accompanies approximately 20-30% of episodes, distinguishing stomatitis herpetiformis from simple recurrent minor aphthous ulcers. Regional lymphadenopathy, particularly submental and submandibular node enlargement, occurs in 40-50% of cases.

Frequency and Duration

Episodes typically recur at 3-6 week intervals, though substantial inter-individual variation exists. Some patients experience monthly episodes, while others develop ulcers quarterly. Without pharmacologic intervention, individual episodes persist 7-14 days, with complete epithelialization often delayed beyond pain resolution.

Importantly, stomatitis herpetiformis typically shows stable, non-progressive course over years. Patients do not develop systemic complications and ulcer frequency does not spontaneously increase, distinguishing this condition from underlying systemic diseases (Behçet's syndrome, aphthous-type oral ulcers in SLE).

Differential Diagnosis from Herpes Simplex Infection

Clinical Distinguishing Features

Herpes simplex infection presents with vesicular lesions preceding ulceration, while stomatitis herpetiformis demonstrates primary ulcerations without vesicular phase. This distinction proves critical but frequently overlooked, as many patients recall painful "blisters" without specifically observing vesicles. Clinician examination during active vesicular phase provides definitive differentiation, though most patients present after vesicles have ruptured.

HSV lesions demonstrate centripetal clustering around a single anatomic site (gingiva and hard palate in primary infection, lips and attached gingiva in recurrent infection), while stomatitis herpetiformis shows diffuse distribution across multiple non-keratinized surfaces. Additionally, HSV recurrences typically follow specific dermatomes and occur at identical anatomic sites between episodes, whereas stomatitis herpetiformis lesions show variable distribution.

Laboratory Differentiation

PCR detection of HSV DNA in oral ulcer exudate provides definitive diagnosis, with >98% sensitivity in patients with active lesions. However, HSV PCR may show positive results in asymptomatic shedding or in immunocompromised patients without active disease, requiring clinical correlation. Importantly, HSV PCR in stomatitis herpetiformis remains negative, providing clear differentiation.

Viral culture requires fresh vesicular fluid for optimal sensitivity and requires 5-7 days for results, limiting acute clinical utility. Serologic HSV IgG antibodies prove unreliable for distinguishing HSV infection from prior exposure, as approximately 70-90% of adults carry HSV antibodies regardless of current disease status.

Histopathologic Features

Biopsy of stomatitis herpetiformis demonstrates vesicle formation with intraepithelial acantholysis and neutrophilic infiltration, mimicking pemphigus vulgaris on superficial examination. However, direct and indirect immunofluorescence testing proves negative for IgG and complement deposition, distinguishing stomatitis herpetiformis from autoimmune blistering diseases. In contrast, HSV biopsy demonstrates ballooning degeneration of epithelial cells with multinucleated giant cells containing Cowdry type A inclusions.

Associated Systemic Conditions

Nutritional Deficiencies

Approximately 20-30% of patients with stomatitis herpetiformis demonstrate deficiencies in iron, zinc, folate, or vitamin B12. Iron deficiency anemia occurs in 15-20%, while zinc insufficiency occurs in 10-15%. While nutritional supplementation may reduce ulcer frequency in deficient patients, the majority of well-nourished patients experience no improvement with supplementation, suggesting nutritional factors as contributing rather than primary causative agents.

Immunologic Considerations

Th1-type immune responses appear dysregulated in stomatitis herpetiformis, with enhanced IL-6, TNF-α, and IL-17 production in affected oral tissues. T-cell infiltration predominates in biopsied lesions, with CD8+ cytotoxic T lymphocytes comprising 40-50% of infiltrating lymphocytes. This immunologic pattern resembles that seen in Behçet's disease, though true Behçet's syndrome (with genital ulceration, ocular involvement, and systemic vasculitis) remains absent in typical stomatitis herpetiformis.

Oral Lichen Planus Association

Approximately 5-10% of patients with stomatitis herpetiformis demonstrate concurrent oral lichen planus (OLP), characterized by reticular white striations on buccal mucosa and tongue. When OLP coexists with herpetiform ulcers, more aggressive immunosuppressive therapy may be warranted. This association suggests potential shared underlying immune dysregulation, possibly involving T-cell-mediated reactions to oral epithelial antigens.

Pharmacologic Management

Colchicine Monotherapy

Colchicine, an alkaloid inhibiting microtubule polymerization and neutrophil migration, demonstrates compelling efficacy in stomatitis herpetiformis at doses of 0.5-1.0 mg twice daily. Mechanism of action involves suppression of neutrophilic infiltration into developing lesions, reducing both lesion incidence and severity. Clinical trials demonstrate 50-70% reduction in ulcer frequency and 40-60% reduction in episode severity within 4-8 weeks of therapy initiation.

Pharmacokinetics require oral administration, with peak plasma concentration occurring at 0.5-2 hours. Approximately 50% renal clearance and 45% hepatic metabolism occur, necessitating dose adjustment in renal impairment. Recommended dosing: 0.5 mg twice daily for mild disease, 1.0 mg twice daily for moderate-to-severe disease.

Side effects include diarrhea (30-40% of patients) and abdominal cramping (20-30%), requiring dose adjustment or discontinuation in 10-15% of patients. Importantly, colchicine demonstrates no mutagenic or teratogenic effects in long-term use, permitting extended therapy. Long-term monitoring requires periodic liver function tests and assessment for medication interactions.

Dapsone Therapy

Dapsone (diaminodiphenyl sulfone) suppresses neutrophilic inflammation through inhibition of myeloperoxidase and neutrophilic oxidative burst. Dosing ranges from 50-200 mg daily, with most clinicians using 100 mg daily. Clinical response typically appears within 2-4 weeks, with 60-75% of patients demonstrating significant improvement (>50% reduction in ulcer frequency).

Mechanism of action differs from colchicine—dapsone directly suppresses oxidative metabolism within neutrophils rather than inhibiting cell migration. This alternative pathway allows combination therapy with colchicine in patients experiencing inadequate response to monotherapy. Combination approaches (colchicine 1.0 mg daily plus dapsone 50-100 mg daily) demonstrate 70-80% response rates in steroid-refractory cases.

Critical toxicity considerations limit dapsone use: hemolytic anemia occurs in 5-10% (particularly in patients with G6PD deficiency), and sulfone-induced agranulocytosis develops in 0.1-0.5% requiring baseline and monthly complete blood counts. Dapsone contraindications include pregnancy (teratogenic), sulfonamide allergy, and moderate-to-severe renal disease.

Topical Corticosteroids

Topical corticosteroid gels (0.1% triamcinolone acetonide, 0.05% fluocinonide) provide symptomatic relief and may reduce individual lesion duration 1-3 days. However, topical steroids show limited efficacy in preventing new lesion formation or reducing episode frequency when used as monotherapy. Application 4-6 times daily to affected areas remains standard practice, though patient compliance proves challenging given frequent application requirements.

Steroid-containing mouth rinses (dexamethasone 0.5 mg/5 mL, used as 5-minute rinses 2-3 times daily) provide better compliance and may reduce pain more effectively than topical gels. However, rinses cannot achieve sustained local concentration on individual ulcers compared to direct gel application.

Systemic Corticosteroids

Prednisone 20-40 mg daily during acute episodes rapidly reduces lesion progression and pain severity, with visible improvement within 24-48 hours. However, systemic corticosteroid use for recurrent episodes carries significant long-term risks (osteoporosis, opportunistic infection, metabolic effects), restricting use to acute intervention rather than maintenance therapy.

Clinicians should reserve systemic corticosteroids for severe episodes causing significant functional disability or affecting patients with underlying immunocompromise where infection risk requires urgent control. Tapering over 7-10 days prevents steroid rebound exacerbation.

Immunosuppressive Agents for Refractory Cases

Patients demonstrating inadequate response to colchicine, dapsone, and systemic corticosteroids require evaluation for underlying systemic disease (Behçet's syndrome, SLE with oral manifestations) and consideration of stronger immunosuppression. Azathioprine 1-2 mg/kg daily, thalidomide 50-100 mg daily (in appropriate populations with strict pregnancy prevention), and biologic therapies (TNF-α inhibitors, interleukin-inhibitors) show promise in anecdotal reports and small case series.

Azathioprine requires baseline TPMT (thiopurine methyltransferase) assessment and periodic monitoring due to risk of myelosuppression. Thalidomide carries severe teratogenic risk and requires enrollment in REMS (Risk Evaluation and Mitigation Strategy) programs. These agents should be managed collaboratively with medical specialists.

Diagnostic Approach and Clinical Assessment

Initial Evaluation

Clinical history should specifically assess: (1) ulcer grouping and coalescence pattern; (2) presence or absence of vesicular precursors; (3) anatomic distribution; (4) episode frequency and duration; (5) associated symptoms (fever, lymphadenopathy); (6) personal or family history of aphthous stomatitis; (7) medication review; (8) nutritional status.

Physical examination should document lesion number, size, coalescence pattern, erythematous halo characteristics, fibrin base appearance, and distribution. Ulcers with necrotic base, irregular borders, or involving keratinized mucosa may suggest alternative diagnoses (traumatic ulcers, oral cancer, squamous cell carcinoma).

When to Biopsy

Biopsy indication exists for: (1) ulcers persisting >3 weeks without healing; (2) lesions with atypical appearance (irregular borders, induration, necrotic base); (3) diagnostic uncertainty regarding HSV versus other diagnoses; (4) suspicion of underlying systemic disease (Behçet's, SLE); (5) failure to respond to standard therapy.

Standard biopsy technique involves 4 mm punch biopsy encompassing both ulcer and erythematous halo. Histopathology demonstrating intraepithelial ulceration without HSV-specific viral inclusions, combined with negative immunofluorescence, confirms aphthous-type ulceration (including stomatitis herpetiformis subtype).

Conclusion

Stomatitis herpetiformis represents a distinct RAS subtype characterized by grouped oral ulcers, differentiated from HSV infection by absence of vesicular phase and negative viral studies. Clinical presentation with dozens to hundreds of small coalescing ulcers creates significant functional disability despite their benign prognosis. Colchicine and dapsone provide evidence-based pharmacologic management, with response rates exceeding 60-70%. Long-term prognosis remains excellent, with spontaneous remission occurring in some patients after years of disease. Early recognition and appropriate pharmacotherapy substantially improve patient quality of life compared to symptomatic management alone.